• Dan Benhamou.
• Service d'Anesthésie Réanimation Médecine Péri Opératoire, AP-HP, Université Paris-Saclay Hôpital Bicêtre, Le Kremlin Bicêtre Cedex, France. Electronic address: dan.benhamou@aphp.fr.
• Br J Anaesth. 2023 Jul 1; 131 (1): 222522-25.

AbstractPostoperative nausea and vomiting (PONV) has been identified as a big (very frequently encountered) little (not linked to life-threatening outcomes) problem. Traditional drugs (dexamethasone, droperidol or similar drugs, serotonin receptor antagonists) each have significant but limited effect, leading to an increasing use of combination therapies. High-risk patients, often identified through use of risk scoring systems, remain with a significant residual risk despite combining up to three traditional drugs. A recent correspondence in this Journal proposes the use of up to five anti-emetic drugs to further minimise the risk. This disruptive strategy was supported by favourable initial results, absence of side-effects and lower acquisition costs of the added new drugs (aprepitant and palonosetron) because of their recent loss of patent protection. These results are provocative and hypothesis generating, but need confirmation and do not warrant immediate changes in clinical practice. The next steps will also necessitate wider implementation of protocols protecting patients from PONV and a search for additional drugs and techniques aimed at treating established PONV.Copyright © 2023 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

22 keywords...

hide…